
Opinion|Videos|May 6, 2024
A New Era in PAH Treatment?
Author(s)Marius Hoeper, MD
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
2
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
3
3 New Study Findings to Look Out for at Menopause Society 2025
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5